The cobas MPX-E test provides four critical results (for HIV, HCV, HBV, and HEV) in a single test, increasing laboratory ...

The assay is developed to address current demands of laboratories.

- More than 15,000 new cases of follicular lymphoma are diagnosed each year in the US, and about 20 percent of patients will relapse within two years, with few treatment options[1] - The new cobas ...

Roche announced today the U.S. Food and Drug Administration (FDA) 510(k) clearance of its newest analytical units – the ...

A test that can detect the DNA of the human papilloma virus (HPV), to confirm the need for cervical cancer screening in women 25 years and older, has gained the FDA’s support as a primary screening ...

Every year, over 600,000 women worldwide are diagnosed with cervical cancer and over 340,000 die from this preventable disease, caused by infection with human papillomavirus (HPV). Nine out of 10 ...

New process allows labs to use same Pap test vial instead of transferring sample to new vial, thus simplifying workflow INDIANAPOLIS, June 26, 2013 /PRNewswire/ -- Roche (SIX: RO, ROG; OTCQX: RHHBY) ...

Multiplex PCR Assay for cobas 4800 system uses self-collected male urine and vaginal swab samples. FDA granted 510(k) clearance for Roche’s cobas® CT/NG Test for detecting Chlamydia trachomatis (CT) ...

The U.S. Food and Drug Administration’s Medical Devices Advisory Committee Microbiology Panel unanimously voted that Roche Molecular Systems’ cobas viral DNA test is safe and effective as a ...

The new test detects up to 25 viruses and bacteria, including SARS-CoV-2, influenza, Bordetella pertussis, and RSV, in a single patient sample.Rapid results enable doctors to make fast, confident and ...

The cobas MPX-E test provides four critical results (for HIV, HCV, HBV, and HEV) in a single test, increasing laboratory efficiency and decreasing healthcare costs.The new test delivers faster turnaro ...